The risk of breast, endometrial and ovarian cancer in users of hormonal preparations

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 3, 2006, Pages 288-296

  Bernstein, Leslie ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; MESTRANOL; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TIBOLONE;

APOPTOSIS; BODY MASS; BREAST CANCER; CANCER RISK; CELL DIVISION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MEGADOSE; DRUG POTENCY; ENDOMETRIUM CANCER; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LONG TERM EXPOSURE; LOW DRUG DOSE; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUATION; MITOSIS; OBESITY; OSTEOPOROSIS; OVARY CANCER; OVULATION; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY;

BREAST NEOPLASMS; CHEMOPREVENTION; CONTRACEPTIVES, ORAL, HORMONAL; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; META-ANALYSIS; META-ANALYSIS AS TOPIC; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 33645232747     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_277.x     Document Type: Short Survey

References (57)

1. Anderson G. L. H. L. Judd A. M. Kaunitz D. H. Barad S. A. Beresford M. Pettinger J. Liu S. G. McNeely A. M. Lopez Effect of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial J. Amer. Med. Ass. 2003 290 1739 1748
2. Bernstein L. B. E. Henderson Hormone intake: Relationship to cancer risk In Cancer prevention Eds.: DeVita V. T. Hellman S. Rosenberg S. A. JB Lippincott Philadelphia 1990 pp. 1 17
3. Brinton L. A. R. N. Hoover the Endometrial Cancer Collaborative Group Estrogen replacement therapy and endometrial cancer risk: unresolved issues Obstet. Gynecol. 1993 81 265 271
4. Casagrande J. T. E. W. Louie M. C. Pike S. Roy R. K. Ross B. E. Henderson "Incessant ovulation" and ovarian cancer Lancet 1979 2 170 173
5. Centers for Disease Control Cancer and Steroid Hormone Study Oral contraceptive use and the risk of endometrial cancer J. Amer. Med. Ass. 1983a 249 1600 1604
6. Centers for Disease Control Cancer and Steroid Hormone Study Oral contraceptive use and the risk of ovarian cancer J. Amer. Med. Ass. 1983b 249 1596 1599
7. Centers for Disease Control Cancer and Steroid Hormone Study Combination oral contraceptive use and the risk of endometrial cancer J. Amer. Med. Ass. 1987 257 796 800
8. Chlebowski R. T. S. L. Hendrix R. D. Langer M. L. Stefanick M. Gass D. Lane R. J. Rodabough M. A. Giilligan M. T. Cyr C. A. Thomson J. Khandekar H. Petrovitch A. McTiernan Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial J. Amer. Med. Ass. 2003 289 3243 3253
9. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies Lancet 1996 147 1713 1727
10. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 1997 350 1047 1059
11. Coughlin S. S. A. G. Giustozzi S. J. Smith N. C. Lee A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer J. Clin. Epidemiol. 2000 53 367 375
12. Glud E. S. K. Kjær B. L. Thomsen C. Hogdall L. Christensen E. Hogdall J. E. Bock J. Blaakaer Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer Arch. Intern. Med. 2004 164 2253 2259
13. Goldin C. L. F. Katz The power of the pill: oral contraceptives and women's career and marriage decisions J. Political Economy 2002 110 730 770
14. Grady D. V. L. Ernster Endometrial cancer In Cancer epidemiology and prevention Eds.: Schottenfeld D. Fraumeni J. F. Jr. Oxford University Press New York 1996 pp. 1058 1089
15. Grady D. T. Gebretsadik K. Kerlikowski V. Ernster D. Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet. Gynecol. 1995 85 304 313
16. Greer J. B. M. Modugno G. O. Allen R. B. Ness Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer Obstet. Gynecol. 2005 105 731 740
17. Hankinson S. E. G. A. Colditz D. J. Hunter T. L. Spencer B. Rosner M. J. Stampfer A quantitative assessment of oral contraceptive use and risk of ovarian cancer Obstet. Gynecol. 1992 80 708 714
18. Hemminki E. D. L. Kennedy C. Baum S. M. McKinlay Prescribing non-contraceptive estrogens and progestogens in the United States, 1974-1986 Amer. J. Public Health 1988 78 1479 1481
19. Henderson B. E. J. T. Casagrande M. C. Pike T. Mack I. Rosario A. Duke The epidemiology of endometrial cancer in young women Brit. J. Cancer 1983 47 749 756
20. Hulka B. S. L. E. Chambless D. G. Kaufman W. C. Fowler B. G. Greenberg Protection against endometrial carcinoma by combination-product oral contraceptives J. Amer. Med. Ass. 1982 247 475 477
21. IMS, America National Prescription Audit IMS America Ambler, PA 1987
22. Kaufman D. G. S. Shapiro D. Slone L. Rosenbert O. S. Miettinen P. D. Stolley R. C. Knapp T. Leavitt W. G. Watring N. B. Rosenshein J. L. Lewlis D. Schottenfeld R. L. Engle Decreased risk of endometrial cancer among oral-contraceptive users New Engl. J. Med. 1980 303 1045 1047
23. Kelsey J. L. V. A. LiVolsi T. R. Holford D. B. Fischer E. D. Mostow P. E. Schwartz T. O'Connor C. White A case-control study of cancer of the endometrium Amer. J. Epidemiol. 1982 116 333 342
24. Key T. J. M. C. Pike The dose-effect relationship between "unopposed" oestrogen and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk Brit. J. Cancer 1988 57 205 212
25. Kumle M. E. Weiderpass T. Braaten I. Persson H. O. Adami E. Lund Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study Cancer Epidemiol. Biomarkers Prev. 2002 11 1374 1381
26. Lacey J. V. Jr. P. J. Mink J. H. Lubin M. E. Sherman R. Triosi P. Hartge A. Schatzkin C. Schairer Menopausal hormone replacement therapy and risk of ovarian cancer J. Amer. Med. Ass. 2002 288 334 341
27. Lee S. A. R. K. Ross M. C. Pike An overview of menopausal estrogen-progestin hormone therapy and breast cancerrisk Brit. J. Cancer 2005 92 2049 2058
28. Magnusson C. J. A. Baron N. Correia R. Bergstrom H. O. Adami I. Persson Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy Int. J. Cancer 1999 81 339 344
29. Marchbanks P. A. J. A. McDonald H. G. Wilson S. G. Folger M. G. Mandel J. R. Daling L. Bernstein K. E. Malone G. Ursin B. L. Strom S. A. Norman P. A. Wingo R. T. Burkman J. A. Berlin M. S. Simon R. Spirtas L. K. Weiss Oral contraceptives and the risk of breast cancer New Engl. J. Med. 2002 346 2025 2032
30. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 2003 362 419 427
31. Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 2005 365 1543 1551
32. Ness R. B. J. A. Grisso J. Klapper J. J. Schlesselman S. Silberzweig R. Vergona M. Morgan J. E. Wheeler and the Share Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives Amer. J. Epidemiol. 2000 152 233 241
33. Newcomb P. A. A. Trentham-Dietz Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States) Cancer Causes Control 2003 14 195 201
34. Pike M. C. L. Bernstein D. V. Spicer The relationship of exogenous hormones to breast cancer risk In Current therapy in oncology Ed.: Niederhuber J. E. Mosby St. Louis, MO 1993 pp. 292 303
35. Pike M. C. B. E. Henderson M. D. Krailo A. Duke S. Roy Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use Lancet 1983 2 926 930
36. Pike M. C. C. L. Pearce R. Peters W. Cozen P. Wan A. H. Wu Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study Fertil. Steril. 2004a 82 186 195
37. Pike M. C. C. L. Pearce A. H. Wu Prevention of cancers of the breast, endometrium and ovary Oncogene 2004b 23 6379 6391
38. Piper J. M. D. L. Kennedy Oral contraceptives in the United States: trends in content and potency Int. J. Epidemiol. 1987 16 215 221
39. Riman T. P. W. Dickman S. Nilsson N. Correia H. Nordlinder C. M. Magnusson I. R. Persson Risk factors for invasive epithelial ovarian cancer: Results from a Swedish case-control study Amer. J. Epidemiol. 2002 156 363 373
40. Rodriguez C. A. V. Patel E. E. Calle E. J. Jacob M. J. Thun Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women J. Amer. Med. Ass. 2001 285 1460 1465
41. Rodriguez G. C. D. K. Walmer M. Cline H. Krigman B. A. Lessey R. S. Whitaker R. Dodge C. L. Hughes Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J. Soc. Gynecol. Invest. 1998 5 271 276
42. Rosenblatt K. A. D. B. Thomas the WHO Collaborative Study of Neoplasia and Steroid Contraceptives Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial cancer Int. J. Cancer 1991 49 870 874
43. Ross R. K. A. Paganini-Hill P. C. Wan M. C. Pike Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J. Natl. Cancer Inst. 2000 92 328 332
44. Schairer C. J. H. Lubin R. Triosi S. Sturgeon L. A. Brinton R. Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk J. Amer. Med. Ass. 2000 283 485 491
45. Schildkraut J. M. B. Calingaert P. A. Marchbanks P. G. Moorman G. C. Rodriguez Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk J. Natl. Cancer Inst. 2002 94 32 38
46. Schlesselman J. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis Hum. Reprod. 1997 12 1851 1863
47. Sit A. S. Y. F. Modugno J. L. Weissfeld S. L. Berga R. B. Ness Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma Gynecol. Oncol. 2002 86 118 123
48. Stadel B. V. The etiology and prevention of ovarian cancer Amer. J. Obstet. Gynecol. 1975 123 772 774
49. Stadel B. V. G. L. Rubin L. A. Webster J. J. Schlesselman P. A. Wingo Oral contraceptives and breast cancer in young women Lancet 1985 2 970 973
50. Stanford J. L. L. A. Brinton M. L. Berman R. Mortel L. B. Twiggs R. J. Barrett G. D. Wilbanks R. N. Hoover Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int. J. Cancer 1993 54 243 248
51. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy J. Amer. Med. Ass. 2004 291 1701 1712
52. UK National Case-Control Study Group Oral contraceptive use and breast cancer risk in young women Lancet 1989 1 973 982
53. Voigt L. F. Q. Deng N. S. Weiss Recency, duration and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA) Cancer Causes Control 1994 5 227 233
54. Weiss N. S. T. A. Sayvetz Incidence of endometrial cancer in relation to the use of oral contraceptives New Engl. J. Med. 1980 302 551 554
55. Whittemore A. S. R. Harris J. Itnyre Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group Amer. J. Epidemiol. 1992 136 1184 1203
56. WHO Collaborative Study of Neoplasia and Steroid Contraceptives Endometrial cancer and combined oral contraceptives Int. J. Epidemiol. 1988 17 263 269
57. Zeleniuch-Jacquotte A. A. Akhmedkhanov I. Kato K. L. Koenig R. E. Shore M. Y. Kim M. Levitz K. R. Mittal U. Raju S. Banerjee P. Toniolo Postmenopausal endogenous oestrogens and risk of endometrial cancer: results from a prospective study Brit. J. Cancer 2001 84 975 981